source
- IQVIA report finds 90% of drugs launched 2016-2020 unlikely to recoup costsIQVIA analyzed 825 novel medicines launched in the United States between 1991 and 2020 and found that profitability has sharply declined over time. For drugs launched from 2016 to 2020, a positive…
- FDA approves Roche's Wilserdly for advanced HR-positive, HER2-negative breast cancer with ESR1 mutationThe U.S. Food and Drug Administration has granted approval to Roche's new oral breast cancer therapy, Wilserdly (giredestrant). The decision clears the way for the drug's launch in the United State…